Clinical trials: Allergen Immunotherapy
- Condition Allergen Immunotherapy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Premenstrual Syndrome
Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel
The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS).
- Trial name
- NCT00866437
- Testing
- Skin test panel
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EVE Medical Systems Ltd.
Type I Hypersensitivity
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Safety and tolerability of different dose combinations of MPL and grass pollen allergen and to identify the highest combinations of MPL and grass pollen allergen which is safe.
- Trial name
- NCT00241410
- Testing
- OralvacB2MPL
- Where
- Germany
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Perennial Allergic Rhinitis With Seasonal Variation
The Efficacy & Safety of the UAS Immunotherapy Protocol
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
- Trial name
- NCT01699659
- Testing
- allergen immunotherapy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Abortion, Recurrent
Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss
The EVE- technology is intended for determination of intolerance or sensitivity to female sex hormones among women with hormone-related conditions and for further treatment by desensitization procedure inducing a tolerance to the…
- Trial name
- NCT01175759
- Testing
- Skin test panel
- Where
- Hungary
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EVE Medical Systems Ltd.
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals